Rocket Pharmaceuticals, Inc. (RCKT) stock
RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.11+0.00 (0.00%)
Close on Nov 18, 2026Market cap $231.62MP/E –Yield –
Rocket Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Rocket Pharmaceuticals's cash was $283.70M at Jun 30, 2026. For fiscal 2025 it was $188.90M, down 49.3% from the year before. Over ten years it grew 5.4% a year on average. The highest annual figure on record is $482.70M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $188.90M | -49.3% |
| FY2024 | Dec 31, 2024 | $372.30M | -8.6% |
| FY2023 | Dec 31, 2023 | $407.50M | +13.9% |
| FY2022 | Dec 31, 2022 | $357.73M | -8.0% |
| FY2021 | Dec 31, 2021 | $388.70M | -19.5% |
| FY2020 | Dec 31, 2020 | $482.70M | +58.7% |
| FY2019 | Dec 31, 2019 | $304.10M | +42.7% |
| FY2018 | Dec 31, 2018 | $213.13M | +113.1% |
| FY2017 | Dec 31, 2017 | $100.01M | -20.9% |
| FY2016 | Dec 31, 2016 | $126.47M | +13.7% |
| FY2015 | Dec 31, 2015 | $111.28M | +2975.7% |
| FY2014 | Dec 31, 2014 | $3.62M | -71.7% |
| FY2013 | Dec 31, 2013 | $12.79M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $283.70M | +4.5% |
| Q1 FY2026 | Mar 31, 2026 | $144.40M | -54.6% |
| Q4 FY2025 | Dec 31, 2025 | $188.90M | -49.3% |
| Q3 FY2025 | Sep 30, 2025 | $222.80M | -5.5% |
| Q2 FY2025 | Jun 30, 2025 | $271.50M | -2.6% |
| Q1 FY2025 | Mar 31, 2025 | $318.20M | -3.7% |
| Q4 FY2024 | Dec 31, 2024 | $372.30M | -8.6% |
| Q3 FY2024 | Sep 30, 2024 | $235.70M | -46.1% |
| Q2 FY2024 | Jun 30, 2024 | $278.80M | -9.2% |
| Q1 FY2024 | Mar 31, 2024 | $330.30M | -8.3% |
| Q4 FY2023 | Dec 31, 2023 | $407.50M | +13.9% |
| Q3 FY2023 | Sep 30, 2023 | $437.20M | +42.6% |
| Q2 FY2023 | Jun 30, 2023 | $307.00M | -4.5% |
| Q1 FY2023 | Mar 31, 2023 | $360.00M | +3.9% |
| Q4 FY2022 | Dec 31, 2022 | $357.73M | -8.0% |
| Q3 FY2022 | Sep 30, 2022 | $306.50M | -27.3% |
| Q2 FY2022 | Jun 30, 2022 | $321.40M | -24.7% |
| Q1 FY2022 | Mar 31, 2022 | $346.60M | -25.7% |
| Q4 FY2021 | Dec 31, 2021 | $388.70M | -19.5% |
| Q3 FY2021 | Sep 30, 2021 | $421.50M | +84.3% |
| Q2 FY2021 | Jun 30, 2021 | $426.80M | +70.9% |
| Q1 FY2021 | Mar 31, 2021 | $466.40M | +69.0% |
| Q4 FY2020 | Dec 31, 2020 | $482.70M | +58.7% |
| Q3 FY2020 | Sep 30, 2020 | $228.70M | -4.9% |
| Q2 FY2020 | Jun 30, 2020 | $249.80M | -3.1% |
| Q1 FY2020 | Mar 31, 2020 | $275.90M | +40.3% |
| Q4 FY2019 | Dec 31, 2019 | $304.10M | +42.7% |
| Q3 FY2019 | Sep 30, 2019 | $240.60M | +50.9% |
| Q2 FY2019 | Jun 30, 2019 | $257.80M | +50.4% |
| Q1 FY2019 | Mar 31, 2019 | $196.60M | +7.6% |
| Q4 FY2018 | Dec 31, 2018 | $213.13M | +113.1% |
| Q3 FY2018 | Sep 30, 2018 | $159.48M | +54.6% |
| Q2 FY2018 | Jun 30, 2018 | $171.47M | +57.7% |
| Q1 FY2018 | Mar 31, 2018 | $182.70M | +59.3% |
| Q4 FY2017 | Dec 31, 2017 | $100.01M | -20.9% |
| Q3 FY2017 | Sep 30, 2017 | $103.13M | -25.0% |
| Q2 FY2017 | Jun 30, 2017 | $108.75M | – |
| Q1 FY2017 | Mar 31, 2017 | $114.71M | – |
| Q4 FY2016 | Dec 31, 2016 | $126.47M | – |
| Q3 FY2016 | Sep 30, 2016 | $137.58M | – |
See a number that looks wrong?